The US Food and Drug Administration (US FDA) has placed an import alert on certain products manufactured at Dabur India’s Silvassa facility, restricting their entry into the United States. The development follows an inspection conducted by the regulator at the plant earlier this year.
Dabur said the import alert applies to products manufactured at the Silvassa facility that are intended for the US market. Under the alert, these products may be detained at US ports without physical examination until the company addresses the regulator’s concerns and meets compliance requirements.
The company, however, clarified that the action is not expected to have a significant impact on its overall business. According to Dabur, exports from the Silvassa facility to the US account for a very small portion of its total revenue. The company added that it remains committed to maintaining high quality standards and is working closely with the US FDA to resolve the issues raised during the inspection.
Dabur assured that it has already initiated corrective and preventive measures at the facility and is engaging with the regulator to secure the removal of the import alert at the earliest. The company emphasized that its products sold in India and other international markets remain unaffected by the development.
Despite the regulatory action, investor reaction remained muted. Dabur shares traded largely steady after the announcement, indicating that the market does not expect a major financial impact from the alert. Analysts noted that the company’s exposure to the US market through the affected facility is limited, reducing concerns about earnings pressure.
The import alert highlights the increasing scrutiny faced by pharmaceutical and healthcare manufacturers exporting products to the United States, one of the world’s most tightly regulated markets. Companies often need to address regulatory observations and implement corrective measures before restrictions are lifted.
Dabur stated that it will continue to cooperate with the US FDA and take all necessary steps to ensure compliance with regulatory standards.
Also Read: Centre bars bulk fuel purchases from retail pumps for 90 days